Catalent Closes Acquisition of Paragon Bioservices
Catalent expands gene therapy capabilities with $1.2-billion acquisition of Paragon Bioservices.
Catalent, Inc. announced on May 20, 2019 the completion of a $1.2-billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing company for gene therapies with expertise in adeno-associated virus vectors. Paragon’s capabilities will enhance Catalent’s biologics business and integrated biopharmaceutical solutions for customers, Catalent reported in a press statement announcing the close of the sale.
Paragon is working on GMP manufacturing projects with more than half of the top 40 leading gene therapy developers worldwide, according to the statement. The company recently opened a commercial manufacturing center near the Baltimore-Washington International airport, which is equipped with several 500-L and 2000-L single-use bioreactors for clinical through commercial material production. The production campus-combined with a leased second building that will be built out for commercial GMP manufacturing-has the potential for more than 425,000-sq.ft. of manufacturing space upon completion, Catalent reports.
Source: Catalent Pharma Solutions
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
